Tonix climbs on partnership to develop mpox vaccine

Tonix Pharmaceuticals Holding

26/08/2024 12:42

** Shares of therapy developer Tonix Pharmaceuticals Holding
 TNXP.O  rise ~10.3% to 37 cents premarket
    ** Company says it is collaborating with Bilthoven
Biologicals to advance its mpox vaccine candidate TNX-801
    ** TNX-801 is a horsepox-based vaccine currently in
preclinical development to prevent mpox and smallpox
    ** Up to last close, stock down 97.4% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))